Navigation Links
AOBO Announces New Product Launch
Date:8/7/2009

    NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ --

                 - Jingwei Capsules Treat Allergy Symptoms -

              - Complements Established Boke Nasal Spray Brand -

          - Diversifies Product Offering with Capsule Formulation -

American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced that the Company has launched a new product for the rhinitis and allergy market, called Jingwei Capsules ("Jingwei"). Jingwei will be manufactured by the Company's Boke subsidiary, and will be marketed throughout China utilizing AOBO's distribution network, including the Company's national hospital and pharmacy distribution network.

Jingwei is an effective, long-lasting, tricyclic antihistamine that selectively antagonizes peripheral H1-receptors. This unique mechanism enables Jingwei to quickly alleviate the symptoms associated with rhinitis, chronic urticaria, itching skin and other allergic skin reactions, but without the common antihistamine side-effects. A branded version of Loratadine, Jingwei is currently reimbursable under China's national insurance program.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are very pleased to be launching the Jingwei Capsule, which is complementary to our market-leading Boke nasal spray. Its major competitor is Schering-Plough's Claritine, whose revenue is estimated to be RMB 1.0 billion at present. Jingwei is an excellent product that is both effective and safe. With AOBO's well-established distribution network, and the strength of the Boke brand, we believe that t
'/>"/>

SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... drug development company specialized in oncology and endocrinology, announced ... direct offering of US$12.1 million of units ... to certain institutional investors. Net proceeds from this offering, ...
... Fla. , June 21 Dyadic International, ... cutting-edge C1 platform technology addresses the needs of the ... scale which efficiently convert biomass into ethanol and other ... engaged the influential consulting firm, The Abraham Group, to ...
... WA , and VANCOUVER , June 21 ... ) announced today the initiation of a Phase 3 ... candidate being developed for the treatment of castrate-resistant prostate ... Cancer SATURN Trial, is the first of three Phase ...
Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Dyadic International Engages The Abraham Group as Strategic Advisor 2Dyadic International Engages The Abraham Group as Strategic Advisor 3Dyadic International Engages The Abraham Group as Strategic Advisor 4OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 5
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... species within a community and are commonly transmitted ... pathogen emergence and therefore has been considered as ... of agricultural importance. Many pathogens like malaria, Lyme ... hosts are commonly transmitted by vectors, and their ...
... Researchers at Yale, in collaboration with NIH researchers, have ... the immune system for detection of parasitic infections, leading ... these infections. , Published in the April 28 issue ... how infectious parasites interface with the immune system--a problem ...
... shows that farmers who used agricultural insecticides experienced ... longer using the products. Data from 18,782 North ... including organophosphates and organochlorines, to reports of reoccurring ... and other neurological symptoms. Some of the insecticides ...
Cached Biology News:A new study examines how shared pathogens affect host populations 2Yale researchers identify molecule for detecting parasitic infection in humans 2Use of Insecticides Linked to Lasting Neurological Problems for Farmers 2
Values of steady state parameters for enzyme activities are determined....
... (PPAR) is a member of a ... factors that heterodimerize with retinoic acid-like ... the regulation of glucose and lipid ... of anti-diabetic agents called thiazolidinediones (TZD) ...
... This protein identification Service includes 1. ... protein spots 3. High-sensitive tryptic in-gel ... of samples for MALDI-MS 5. Acquisition ... via MALDI-MS (Bruker ultraflex TOF/TOF) 6. ...
... Preparation Reconstitution: one vial contains ... ficoll and 50 mg PVP; ... water yields a 50concentrate Special ... 1.00 g/mL (20 C) Quality ...
Biology Products: